Abstract
There are limited data regarding the impact of asymmetric stent expansion on subsequent stent coverage and neointimal hyperplasia (NIH) in the contemporary drug-eluting stent era. EGO-BIOFREEDOM (BioFreedom stent in 105 lesions, 99 pts) and EGO-ORION (randomized Resolute vs BioMatrix stent in 119
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
